While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Kleenex and Ghirardelli Chocolate are among the 500 brands that Americans trust the most, according to new research from USA ...
Pharmaceutical Technology on MSN1d
Big pharma faces headwinds in China as vaccine sales declineMultinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.
The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
At Tata Consumer Products, Das drives growth strategy, outcomes and profit & loss for the packaged beverages category in ...
Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback